Home
KZIA
KZIA News

Latest Kazia Therapeutics Limited (KZIA) News on July 14, 2025

Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)

Simply Wall St.

a month ago

Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)

MT Newswires

a month ago

Top Midday Gainers

MT Newswires

a month ago

Kazia Therapeutics Says Preclinical Data Show Paxalisib's Potential in Reducing Breast Cancer Symptoms; Shares Jump

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

PR Newswire

a month ago

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

MT Newswires

a month ago

Kazia Therapeutics Doses First Patient in Phase 1 Trial of Paxalisib for Advanced Breast Cancer

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

PR Newswire

a month ago

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

PR Newswire

2 months ago

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

PR Newswire

3 months ago

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

PR Newswire

5 months ago

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?

Insider Monkey

5 months ago

Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?

MT Newswires

5 months ago

Sector Update: Health Care Stocks Gain Thursday

MT Newswires

5 months ago

Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

PR Newswire

5 months ago

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?

Insider Monkey

6 months ago

Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

PR Newswire

6 months ago

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering

TipRanks

6 months ago

Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering

MT Newswires

6 months ago

Kazia Therapeutics Launches $2 Million Registered Direct Offering

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

PR Newswire

6 months ago

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Benzinga

6 months ago

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

MT Newswires

6 months ago

Update: Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug

MT Newswires

6 months ago

Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

PR Newswire

6 months ago

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

PR Newswire

7 months ago

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

PR Newswire

8 months ago

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing

TipRanks

9 months ago

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

PR Newswire

9 months ago

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

PR Newswire

10 months ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

MT Newswires

10 months ago

Kazia Therapeutics Executes Deal With QIMR Berghofer Medical to Obtain Intellectual Property License

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

PR Newswire

10 months ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Zacks

a year ago

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Kazia Therapeutics stocks soar following Phase II/III win

Clinical Trials Arena

a year ago

Kazia Therapeutics stocks soar following Phase II/III win

MT Newswires

a year ago

Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

PR Newswire

a year ago

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

PR Newswire

a year ago

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

PR Newswire

a year ago

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

Kazia concludes first stage of Phase I advanced cancer treatment trial

Clinical Trials Arena

a year ago

Kazia concludes first stage of Phase I advanced cancer treatment trial

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

PR Newswire

a year ago

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

11 Best ASX Stocks To Buy Now

Insider Monkey

a year ago

11 Best ASX Stocks To Buy Now

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

PR Newswire

a year ago

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Kazia announces presentation of new data at AACR Annual Meeting

PR Newswire

a year ago

Kazia announces presentation of new data at AACR Annual Meeting

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

PR Newswire

a year ago

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock

Simply Wall St.

a year ago

Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock

GlobeNewswire

a year ago

TRUGOLF, INC. AND DEEP MEDICINE ACQUISITION CORP. CLOSE BUSINESS COMBINATION; TRUGOLF BECOMES PUBLICLY TRADED COMPANY

Paragon Calls Out OPT’s Inaccurate Statements About Voting on the Blue Proxy Card; Vote the Blue Proxy Card and Put an End to the Corporate Greed and Drowning Share Price

ACCESSWIRE

a year ago

Paragon Calls Out OPT’s Inaccurate Statements About Voting on the Blue Proxy Card; Vote the Blue Proxy Card and Put an End to the Corporate Greed and Drowning Share Price

GlobeNewswire

a year ago

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 23, 2024

Red Cat to Participate in the 2024 SHOT Show

GlobeNewswire

a year ago

Red Cat to Participate in the 2024 SHOT Show

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

PR Newswire

a year ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

GlobeNewswire

2 years ago

TRUGOLF, INC. AND NASDAQ-LISTED SPAC DEEP MEDICINE ACQUISITION CORP. ANNOUNCE FORM S-4 REGISTRATION STATEMENT DECLARED EFFECTIVE BY THE U.S. SECURITIES AND EXCHANGE COMMISSION AND MAILING OF DEFINITIVE PROXY STATEMENT

Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support

PR Newswire

2 years ago

Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support

DarioHealth (NASDAQ:DRIO) shareholders are up 38% this past week, but still in the red over the last five years

Simply Wall St.

2 years ago

DarioHealth (NASDAQ:DRIO) shareholders are up 38% this past week, but still in the red over the last five years

MariaDB Reaches Agreement to Amend Senior Secured Promissory Note

Business Wire

2 years ago

MariaDB Reaches Agreement to Amend Senior Secured Promissory Note

Vicinity Motor Corp. Issues DSUs

ACCESSWIRE

2 years ago

Vicinity Motor Corp. Issues DSUs

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

2 years ago

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Immunic, Inc. Announces Private Placement of up to $240 Million

PR Newswire

2 years ago

Immunic, Inc. Announces Private Placement of up to $240 Million

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

2 years ago

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

GlobeNewswire

2 years ago

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Red Cat Endorses Passing of the American Security Drone Act

GlobeNewswire

2 years ago

Red Cat Endorses Passing of the American Security Drone Act

$BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset$

GlobeNewswire

2 years ago

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

Millennium Group International Holdings Celebrates Prestigious Award Win at Manufacturing Asia Awards

GlobeNewswire

2 years ago

Millennium Group International Holdings Celebrates Prestigious Award Win at Manufacturing Asia Awards

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate

GlobeNewswire

2 years ago

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate

NextCure Provides Year-End Clinical Pipeline Updates

GlobeNewswire

2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

Aurora Mobile’s Subsidiary SendCloud Provides Email Services to Rain Classroom to Help Drive User Outreach

GlobeNewswire

2 years ago

Aurora Mobile’s Subsidiary SendCloud Provides Email Services to Rain Classroom to Help Drive User Outreach

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

PR Newswire

2 years ago

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Cumulus Media Taps Collin Jones to Lead Westwood One

GlobeNewswire

2 years ago

Cumulus Media Taps Collin Jones to Lead Westwood One

Global Self Storage Declares Fourth Quarter 2023 Dividend

ACCESSWIRE

2 years ago

Global Self Storage Declares Fourth Quarter 2023 Dividend

Kazia Therapeutics Announces $2 Million Registered Direct Offering

PR Newswire

2 years ago

Kazia Therapeutics Announces $2 Million Registered Direct Offering

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

PR Newswire

2 years ago

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

Zacks

2 years ago

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections

GlobeNewswire

2 years ago

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections

Casa Systems Sets Cable Industry Milestone with DOCSIS 4.0 Extended Spectrum Breakthrough

GlobeNewswire

2 years ago

Casa Systems Sets Cable Industry Milestone with DOCSIS 4.0 Extended Spectrum Breakthrough

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

PR Newswire

2 years ago

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

PR Newswire

2 years ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week

Simply Wall St.

2 years ago

Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week

Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts

PR Newswire

2 years ago

Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

GlobeNewswire

2 years ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

PR Newswire

2 years ago

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Associated Press Finance

2 years ago

Crown Crafts: Fiscal Q2 Earnings Snapshot

Crown Crafts Announces Financial Results for Second Quarter Fiscal 2024 and Declares Quarterly Dividend

GlobeNewswire

2 years ago

Crown Crafts Announces Financial Results for Second Quarter Fiscal 2024 and Declares Quarterly Dividend

After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)

Zacks

2 years ago

After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)

Downgrade: Here's How Analysts See FTC Solar, Inc. (NASDAQ:FTCI) Performing In The Near Term

Simply Wall St.

2 years ago

Downgrade: Here's How Analysts See FTC Solar, Inc. (NASDAQ:FTCI) Performing In The Near Term

CXApp Inc. (Nasdaq:CXAI) Schedules Third Quarter 2023 Financial Results and Business Update Conference Call

ACCESSWIRE

2 years ago

CXApp Inc. (Nasdaq:CXAI) Schedules Third Quarter 2023 Financial Results and Business Update Conference Call

American Oncology Network’s Specialty Pharmacy Reports Zero Drug Waste After Value-Based Trial, Secures Unchanged Reimbursement Rate for 2024

GlobeNewswire

2 years ago

American Oncology Network’s Specialty Pharmacy Reports Zero Drug Waste After Value-Based Trial, Secures Unchanged Reimbursement Rate for 2024

Telesat Reports Results for the Quarter and Nine Months Ended September 30, 2023

GlobeNewswire

2 years ago

Telesat Reports Results for the Quarter and Nine Months Ended September 30, 2023

Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Q3 2023 Earnings Call Transcript

BK Technologies to Introduce InteropONE Tethering Feature Enabling Push-To-Talk-Over Broadband Capabilities for BKR 5000 and BKR 9000 Radio Customers

ACCESSWIRE

2 years ago

BK Technologies to Introduce InteropONE Tethering Feature Enabling Push-To-Talk-Over Broadband Capabilities for BKR 5000 and BKR 9000 Radio Customers

Share on Social Networks: